Akums Reports Strong FY26 Performance Driven by Global CDMO Business

Akums Drugs and Pharmaceuticals Ltd reported consolidated FY26 revenue of ₹4,359 crore, a 5.9% year-on-year increase, and its adjusted profit after tax surged 27.3% to ₹276 crore.

Strong Full-Year and Fourth Quarter Performance

Akums Drugs and Pharmaceuticals Ltd unveiled robust financial results for the fiscal year ending March 31, 2026. Consolidated operating revenue for FY26 stood at ₹4,359 crore, marking a 5.9% year-on-year growth.

The company's adjusted EBITDA saw a healthy increase of 13.3% to ₹522 crore, while adjusted profit after tax (PAT) leaped by 27.3% to ₹276 crore.

Performance in the fourth quarter (Q4 FY26) was particularly strong, with revenue up 9.7% to ₹1,158 crore. Adjusted EBITDA surged 61.6% to ₹152 crore, and adjusted PAT more than doubled, growing 135% to ₹83 crore.

The Board recommended a final dividend of ₹1 per share and a special dividend of ₹2 per share, totaling ₹3 per share.

Global Expansion Drives Growth

The strong financial performance is underpinned by Akums' growing role as a global pharmaceutical player and its successful domestic Contract Development and Manufacturing Organisation (CDMO) business. Significant progress in regulated markets, including commercial supply to Europe and EU GMP certifications, shows the company's expanding global footprint and adherence to international quality standards. Approvals from the UK MHRA for a key drug and Brazil's ANVISA for its injectable plant, along with the start of its Zambia manufacturing facility, signal strategic international diversification and market access. This expansion is solidifying the company's position in regulated markets, which typically offer higher margins, and is diversifying its revenue streams to reduce reliance on any single market.

Strategic International Push

Akums has been strategically expanding its international footprint over recent years, aiming to obtain approvals from stringent regulatory authorities like EU GMP, US FDA, and UK MHRA. This expansion includes establishing manufacturing capabilities and obtaining certifications to cater to diverse global markets, from Europe to Africa.

API Business Faces Pricing Pressures

The Active Pharmaceutical Ingredient (API) business segment continues to grapple with pricing pressures, resulting in an operating loss of ₹12 crore in Q4 FY26 and an EBITDA loss of ₹40 crore for the full fiscal year.

Industry Context

While peers like Syngene International focus on integrated CDMO services driven by innovator contracts, Akums is demonstrating a strong push into manufacturing for regulated markets and establishing international production bases.

Divi's Laboratories, a major API player, has historically managed API margin pressures through scale, an area Akums is also focused on but faces its own segment-specific challenges.

Financial Performance Over Two Years

Consolidated operating revenue increased 5.9% year-over-year, from ₹4,118 crore in FY25 to ₹4,359 crore in FY26. Adjusted EBITDA rose 13.3% from ₹461 crore to ₹522 crore. Adjusted profit after tax (PAT) surged 27.3%, from ₹217 crore in FY25 to ₹276 crore in FY26.

Looking Ahead

Moving forward, the company is expected to focus on portfolio optimization and cost control to sustain growth. Key areas to watch include the execution of its international expansion strategy, particularly the operationalization of the Zambia plant. Management's ability to navigate pricing pressures in the API segment while fostering CDMO growth, alongside securing further regulatory approvals in key global markets, will be crucial.